Back to top

messenger-rna: Archive

Zacks Equity Research

FDA Accepts GSK Filing for Expanded Use of RSV Shot in Younger Adults

FDA accepts GSK's filing to extend Arexvy's RSV vaccine use to high-risk adults under 50, with a decision due in 2026.

GSKNegative Net Change PFENegative Net Change MRNAPositive Net Change